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Abstract: 
The blood–brain barrier (BBB) plays a fundamental role in protecting the brain from toxic substances and therefore 
also controls and restricts the entry of therapeutic agents. The nasal administration of drugs using the nose-to-brain 
pathway allows direct drug targeting into the brain, avoiding the first-pass effect and bypassing the BBB. Through 
the nasal route, the drug can access the brain directly along the trigeminal and olfactory nerves, which are located 
in the upper part of the nasal cavity. Nanoemulsions are formulations belonging to the field of nanomedicine. They 
consist of emulsions (commonly oil in water) stabilized by one or more surfactants—and eventually co-surfactants—
delivered in droplets of small dimensions (sizes of 100–300 nm or less) with a high surface area. A mucoadhesive 
polymer such as chitosan can be added to the formulation to impair rapid nasal clearance. Nanoemulsions 
represent promising formulations to deliver drugs directly into the brain through the intranasal route. Therefore, 
they can be used as a possible alternative to oral administration, avoiding problems such as low solubility in water, 
poor bioavailability, enzymatic degradation and slow onset of action. This review focuses the present situation in 
literature regarding the use of Nanoemulsions for nose-to-brain targeting, with particular attention to recent 
publications. Nasal Nanoemulsions appear to be effective, non-invasive and safe drug delivery systems to achieve 
brain targeting for the treatment of neurological diseases. 
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pathway. 
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The microvasculature of the central nervous system 
(CNS) is defined as a blood–brain barrier (BBB) 
because it isolates the brain from the remaining part 
of the body. CNS vessels, at the levels of arteriole–
capillary–venules are non-fenestrated and 
continuous; they are able to control the exchange of 
molecules, ions and cells between the blood and the 
brain [1]. This strong barrier capacity allows the BBB 
to protect the CNS from pathogens, toxins and 
external agents. The barrier structure of BBB 
depends on the specific properties of the brain 
endothelial cells (BECs) that constitute the walls of 
the blood vessels. BECs are different from 
endothelial cells of non-neural tissues—they are 
polarized cells, held together by tight junctions that 
strongly limit them paracellular flux of solutes 
(molecules and ions) and restrict vesicle-mediated 
transcellular transports (Pinocytosis/transcytosis) 
.[1,2].  BECs are characterized by two kinds of 
systems of transport in both directions that include 
the expression of efflux transporters, whose function 
is the elimination of the lipophilic toxins able to 
passively diffuse through the cell membrane, and the 
expression of influx transporters, which are specific 
carriers that deliver the nutrients across the BBB into 
the brain .[1] Among efflux transporters, P-
glycoprotein plays an important role, as its activity 
has been associated with diseases of the CNS such as 
drug-resistant tumors and epilepsy.[1] BBB is not 
only a cellular self-defense barrier but also an active 
interface that strictly controls the CNS 
microenvironment, allowing its normal neuronal 
functions. BBB cells are able to communicate with 
CNS cells and they adapt their behavior to the needs 
of the CNS, responding to pathological conditions 
and sometimes becoming a cause of the progression 
of the disease. [1]. Neurological diseases, such as 
neuroinfections, Parkinson’s disease, Alzheimer’s 
disease, multiple sclerosis, chronic age-related 
neurodegenerative diseases, cerebral ischemia and so 
on represent a group of severe pathologies with a 
broad spectrum of pathological conditions that result 
in alterations of neural functions. Healthcare statistics 
confirm that the incidence of CNS diseases is rapidly 
increasing around the world with higher healthcare 
costs. [5]. The nose is responsible both for respiration 
and for olfaction. The human olfactory region, where 
olfactory and trigeminal nerve terminations are 
present, occupies 2–12.5 cm2, representing 
approximately 1.25–10% of the total surface area of 
the nasal cavity, and it is about 60 _m thick [6]. 
Olfactory and trigeminal pathways are the only routes 
by which the brain is connected to the outside 
environment.[8,9] Thanks to the direct connection 
provided by the olfactory and trigeminal nerves 
present between the olfactory epithelium and the 
brain, drug targeting can be achieved with the 
administration of formulations onto nasal mucosa 
[10,12].  Therefore, particular attention must be given 
to studies of the blood–nerve barrier (BNB), which 
consists of endoneurial microvessels within the nerve 
fascicle and the investing perineurium [13, 14]. These 
microvessels are actively involved in the mechanisms 
that regulate the permeability of the perineurium and 
endoneurial capillaries, and surely they play an 
important role in the passage of substances from 
olfactory and trigeminal pathways into the CNS. 
Nose-to-brain drug delivery is a painless, non-
invasive administration route that can be used to 
deliver therapeutic agents into the brain by bypassing 
the BBB.[10,14,17] These drug administration 
pathways are characterized by many advantages such 
as increased patient compliance, high safety, 
remarkable ease of administration and rapid onset of 
action, as well as minimized systemic exposure [7] .  
Furthermore, the use of nasal mucosa as a route of 
drug administration permits drugs to avoid hepatic 
first-pass metabolism. Consequently, nasal doses are 
often 2–10 times lower than oral doses. Direct 
transport of drug to brain through nasal 
administration is therefore more promising than oral 
or intravenous routes of administration [18]. 
However, despite its numerous advantages, nose-to-
brain drug delivery can be limited by possible low 
bioavailability due to enzymatic degradations of 
sensitive drugs onto the mucosal surface, high 
clearance and restrictions determined by the anatomy 
of the nasal cavity (e.g., small volume, limited 
surface area of the olfactory mucosa, mucociliary 
clearance, etc.). These problems should be correctly 
addressed in designing suitable nose-to-brain 
formulations (Figure 1). Despite these limitations, 
examples of promising results are present in clinical 
trials [19, 20] According to the present literature, 
different kinds of nanocarriers are used to prepare 
nasal formulations able to target the brain, constituted 
by polymer-based and lipid-based nanoparticles [21–
23]. 
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Figure 1. The nose as a route for the administration of drugs. 
General Characteristics of NEs in Brief: 
Nanoemulsions (NEs) are oil-in-water (O/W) or 
water-in-oil (W/O) dispersions of two immiscible 
liquids stabilized using appropriate surfactant(s)[24]  
, with a mean droplet diameter of about 100 nm ,[25]  
even if in literature upper size limits up to 300 
nm[26].  have been reported. As the size of the 
droplets is significantly smaller than the wavelength 
of visible light, NEs have either a transparent or from 
transparent-to-milky-white appearance[25]. NEs can 
be formulated into different kinds of dosage forms 
like liquids, creams, gels, foams, sprays and so on, 
and can be administered by different routes including 
oral, parenteral and ocular, in addition to nasal [27] . 
NEs have droplets of a small size and therefore they 
are characterized by a higher surface area with 
respect to other formulations, and by a long-term 
physical stability, because the small droplet size 
impairs destabilization phenomena like coalescence, 
creaming and sedimentation. NEs can be used to 
solve problems of drug solubility and/or of drug 
stability (oxidation, pH, hydrolysis and enzymatic 
degradation at the mucosal level, under physiological 
conditions) . Hydrophobic drugs are expected to 
dissolve in the oily phase, and when the drug 
(dissolved in the oily phase) is released from the NE 
and comes in contact with the surrounding aqueous 
environment, a nanoprecipitation can occur. This 
determines the formation of particles with an 
enormously high surface and a remarkable 
improvement of drug dissolution rate, according to 
the Noyes–Whitney equation [29] . NEs can be used 
also to mask the bitter or unpleasant taste of drugs 
and to carry products of natural origin [30,31]. The 
preparation methods of NEs have been reviewed in 
exhaustive papers [24,32]. According to these 
authors, NEs can be prepared through different 
techniques that can be classified into two broad 
categories: high-energy methods and low-energy 
methods (Figure 2). In the case of high-energy 
methods, such as ultrasonication and high pressure 
homogenization, the constitution of the small droplets 
involves a mechanical device that generates 
disruptive forces breaking up oil and water phases to 
produce small oil droplets, a process that consumes 
significant energy. The devices used are  
microfluidic, ultrasound or high pressure 
homogenizers [33]. 
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                                                  Figure 2. Preparation methods of nanoemulsions (NEs). 
The low-energy methods involve specific physico-
chemical processes such as phase inversion 
temperature and emulsion inversion points to make 
small droplets without consuming significant energy. 
In the low-energy methods, the droplets are 
constituted when the system undergoes an inversion 
of phase in response to changes, such as composition 
or temperature, and consequently passes through a 
low interfacial tension state [32]. The quantity of 
lipidic component(s) used in NEs is dependent on the 
kind of emulsion (generally they contain 5–20% 
lipidic droplets in cases of O/W emulsion) and on 
solubility of the drug to loaded in the system [29] . 
The solubilizing capacity of the oil phase is a factor 
that plays an important role in the oil selection 
because the oil phase must dissolve and maintain 
dissolved the drug. Furthermore, the highest possible 
solubility is required to decrease the amount of oil 
used, reducing the required amounts of surfactants 
that might determine toxicity problems [34]. Usually 
the lipids used for the preparation of NEs, alone or in 
mixture, are fractions of oils of natural origin such as 
sesame oil, cottonseed oil, soybean oil, coconut oil, 
and so on that can be classified according to chain 
lengths as long-chain, medium-chain and short-chain 
triglycerides [29] . The kind of oil components used 
in the formulation process of NEs influences 
(sometimes strongly) the bioavailability of the drug. 
Many studies have been performed to clarify this 
aspect for oral NE delivery. For example, it is 
reported that the bioavailability of curcumin is 
maximized in NEs made with medium-chain and 
long-chain triglycerides [35]  . Furthermore, it has 
been reported that several NEs are characterized by a 
direct lymphatic absorption (avoiding first-pass 
metabolism) [29]  and it is likely that this behavior 
strongly depends on lipidic phase composition. No 
data seem available at the momentregarding the 
relevance of oil choice for nasal and in particular for 
nose-to-brain administration [37]. Emulsifiers are 
needed to facilitate NE formation and to ensure its 
kinetic stability during storage, even if NEs typically 
require less surfactant than other colloidal 
dispersions. The emulsifier used for the preparation 
of NEs is very often a surfactant, but proteins and 
lipids have also been used. Lecithin 
(phosphatidylcholine) [36] , sodium deoxycholate 
(bile salt) [37] , polyoxyethlene sorbitan monolaurate 
(Tween 20, 40, 60, 80)[39] and sorbitan monolaurate 
(Span 20, 40, 60, 80) [38]are commonly employed in 
the preparation of NEs. Other surfactants proposed 
are poloxamers ,[40] sodium dodecyl sulfate[41] , 
amphiphilic proteins like casein ,[42] polysaccharides 
(starch derivatives, gums)  and poly-ethylene-glycol 
(PEG)-containing block copolymers .[44] Co-
surfactants, such as polyethylene glycol, ethylene 
glycol, propylene glycol, ethanol and glycerine can 
be used for the stabilization of NEs . All of these can 
be used alone or in combination. 
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The selection of the surfactants is critical, as they 
must be safe at the concentrations used. The choice 
of the surfactant or of the surfactant blend influences 
both the size of the droplets and the stability of the 
NE. However, it must be taken into account that this 
choice can influence pharmacokinetics and toxicity; 
for example, poloxamer 188 has renal toxicity at a 
concentration higher than 0.5% in parenteral NEs 
[29]. 
 
Generally speaking, these formulations appear safe 
because, to our knowledge, no mutagenic effects are 
reported in literature, and only safe pharmaceutical 
excipients have been used for their preparation. In the 
present literature there is some confusion regarding 
the classification of NEs because they are sometimes 
confused with microemulsions, which are 
thermodynamically stable systems that form 
spontaneously [24,46]  . For this reason, 
macroemulsions and NEs can be prepared with high- 
and low-energy methods, while microemulsions are 
prepared with low-energy methods only. Important 
differences can be found between classical 
macroemulsions (classical emulsions), NEs and 
microemulsions in droplet size range and stability 
characteristics [32,47]. 
 
General Overview of NEs for Nose-to-Brain 
Delivery: 
The easiest classification of NEs designed for nose-
to-brain delivery is based on the drug loaded and the 
therapeutic purpose. As the final target is the brain 
through the nose, the pharmacological actions regard 
pathologies of the CNS. In one case, a probe is 
loaded in the NE to obtain brain imaging. The 
formulations used in the intranasal administrations of 
drugs are always, in our knowledge, O/W emulsions. 
A general overview of the present literature about 
NEs for nose-to-brain targeting shows clearly that 
intranasal use is often an alternative to the oral 
therapy. In fact, if the drug is administered orally to 
reach the brain, this kind of administration can 
present problems for some drugs, which are 
summarized in Table 1. CNS delivery through the 
nasal mucosa sometimes performs better than 
parenteral administration as well, as shown by in vivo 
experiments. One of the first examples in the 
literature of the use of NEs to reach the brain through 
the administration onto nasal mucosa is a paper by 
Kumar et al. in which NEs were utilized to carry 
risperidone, an antipsychotic drug belonging to the 
group of benzisoxazole derivatives [48]. According 
to the authors’ opinion, these positive results were 
related to the enhancing of the nasal retention time 
due to the presence of chitosan, thus confirming the 
importance of this polymer as mucoadhesive agent in 
nasal formulations [50]. 
 
Table 1. Characteristics that make the central nervous system (CNS) drug a candidate for nasal NE, as an alternative 
to oral administrations. 
 
Low capacity to cross the Blood-Brain-Barrier 
Low solubility in water (and consequently poor bioavailability) 
Low/irregular absorption (and consequently poor bioavailability) 
Active substrate of intestinal P-glycoprotein 
Problems of stability (pH, hydrolysis, oxidation, under gastro-intestinal conditions) 
Intestinal metabolism (enzymatic degradation) 
First-pass metabolism (enzymatic degradation) 
Need to reduce dosage (i.e., in case of chronic therapy and/or to avoid side effects connected to the high oral 
dosage used for overcoming the Blood-Brain-Barrier) 
Slow onset of action 
Bitter/unpleasant taste of the drug 
 
An important application of nose-to-brain delivery 
with NEs was that described by Mahajan et al., who 
used NEs to carry anti-HIV drugs [28] . It is known 
that after the initial infection, CNS is the region in 
which HIV viruses constitute a sort of “anatomic 
reservoir”, and from which they can reactivate the 
infection. Furthermore, the brain infection from HIV 
can determine neuro-AIDS, a form of dementia and 
cognitive impairment. It is clear that improved drug 
delivery to the CNS will reduce the possibility of 
underlying persisting infections. Saquinavir mesylate 
is a protease inhibitor with activity against HIV-Type 
1 (HIV-1). However, its bioavailability is low, owing 
to its low solubility in water. Furthermore, saquinavir 
permeability through the BBB is poor and is a P-
glycoprotein and cytochrome P450 substrate. For all 
IAJPS 2019, 06 (05), 9154-9163                  Rahul  Dhangar et al                     ISSN 2349-7750 
 
 w w w . i a j p s . c o m  
 
Page 9159 
these reasons, nasal O/W NEs containing saquinavir 
mesylate were prepared by the spontaneous 
emulsification technique using Capmul MCM, a 
mono-diglyceride of medium-chain fatty acids 
(mainly caprylic and caproic). NEs were 
characterized in terms of drug content, droplet size 
and zeta potential. Ex vivo permeation studies were 
carried out using excised fresh sheep nasal mucosa. 
NEs showed an increase in drug permeation 
compared to plain drug suspension. Cilia toxicity was 
low. In vivo biodistribution studies, carried out after 
nasal administration of 99mTc formulations, showed 
higher drug concentration in the brain after nasal 
administration of NE with respect to intravenous 
administration. Gamma scintigraphy imaging of a rat 
brain demonstrated increased drug transport to the 
CNS after NE nasal administration. One of the most 
recent papers published on the use of NEs for nose-
to-brain delivery is by Haider et al., who prepared 
rivastigmine NEs for enhanced brain delivery 
through nasal administration .[53] Rivastigmine 
hydrochloride is a drug that has been proposed for the 
therapy of Alzheimer’s disease, as it helps in 
prevention of acetylcholine hydrolysis through the 
enzymes acetylcholinesterase and 
butyrylcholinesterase and thereby increases central 
cholinergic function and availability of acetylcholine. 
Box–Behnken design was used to statistically 
optimize the formulation parameters for the 
preparation of NEs. Ex vivo diffusion studies were 
carried out using Franz diffusion cells through freshly 
excised goat nasal mucosa. In vivo studies were 
carried out on Wistar rats. For the preparation of 
NEs, the selection of the oils led to the choice of 
Capmul MCM, whereas among surfactants Tween 80 
and among co-surfactants Transcutol-P were chosen. 
Ex vivo diffusion studies done on goat nasal mucosa 
showed that the cumulative amount of drug 
permeation through nasal mucosa for NE was higher 
than that of the drug solution used as a comparison. 
In vivo studies showed that the brain drug 
concentration after nasal administration of NEs was 
significantly higher than that achieved after nasal 
administration of solutions and intravenous 
administration of NEs. NEs loaded with 
chloramphenicol, based on palm kernel oil esters and 
suitable for meningitis treatment have been described 
[54,55] , even if no specific indication about the 
possible nasal use of these formulations has been 
given. NEs containing amiloride have been prepared 
and administered intranasally in mice. Oleic acid, 
Tween 20 and Carbitol were employed as oil, 
surfactant and co-surfactant, respectively. For the 
emulsion preparation, a high-energy ultra-sonication 
method was used. An enhanced drug brain 
bioavailability was found as compared to intravenous 
administration [56]. Lastly, a paper by El-Zaafarany 
et al. describes lipid-based nanovectors defined as 
emulsomes and containing oxcarbazepine [57]  . 
These dispersed systems can be considered the 
borderline between NEs and Solid Lipid 
Nanoparticles (SLNs). In fact, according to the 
authors, in the emulsomes the dispersed phase is 
constituted by “particles” comprising lipid cores 
stabilized by phospholipid layer(s) that surrounds the 
lipid core at the aqueous interface. The lipidic core of 
these particles is in a solid phase, rather than oil in a 
fluid phase. Oxcarbazepine is a drug used for the 
treatment of epilepsy. The aim of this work was the 
preparation of this lipidic nanocarrier aimed at a 
direct nose-to-brain targeting. Ex vivo studies carried 
out using rat nasal mucosa to check possible changes 
induced by Emulsomes showed no histopathological 
alteration. Pharmacokinetic studies carried out in rats 
showed that oxcarbazepine-loaded emulsomes 
slowed drug elimination, and a high drug 
concentration was achieved in the blood stream for a 
longer time periods, as compared to the free drug 
administrations. In Table 2 the schematic 
classification based on drug loaded in NEs is 
reported. 
 
Table 2. Nanoemulsions designed for nose-to-brain delivery, and classification based on the drug. 
Drug/Probe                                                           Therapy of                                                            
Risperidone                                                       Schizophrenia  
Olanzapine                                                        Schizophrenia  
Ergoloid mesylate                                             Antiaging  
Amiloride                                                         Antiepileptic  
Ziprasidone hydrochloride                               Antipshychotic  
Saquinavir mesylate                                         HIV infections  
Nimodipine                                                       Cerebrovascular spasm and senile  dementia                                                                               
Curcumin                                                          Neurodegenerative diseases  
Resveratrol                                                        Parkinson’s disease  
Curcumin/Resveratrol                                      Age-related neurodegenerative diseases  
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Cyclosporine-                                                   A Neuro-protective  
anti-TNF_                                                         RNA Neuro-inflammations  
Riluzole Amyotrophic                                      lateral sclerosis (ALS)  
Selegiline                                                          Parkinson’s disease  
Thymoquinone                                                 Cerebral ischemia  
Paroxetine                                                        Depression and anxiety  
Quetiapine                                                        Schizophrenia  
Zolmitriptan                                                      Migraines  
Aggregation-                                                    caused quenching (ACQ) probes Labeling action  
Kaempferol                                                      Gliomas  
Rivastigmine                                                    Alzheimer’s disease             
Chloramphenicol                                             Bacterial meningitis 
Amiloride                                                        Epilepsy  
Oxcarbazepine                                                 Epilepsy 
 
CONCLUSIONS: 
Nanoemulsions are formulations that are more and 
more important in the field of nanomedicine. Their 
characteristics (nanodroplets with a high surface) 
make them suitable for nose-to-brain delivery. 
Mucoadhesive polymers can be added in their 
composition to slow down nasal clearance. The 
presence of chitosan as an additional excipient plays 
a double role, because it is mucoadhesive and has 
penetration enhancing properties on nasal mucosa. As 
shown by Table 2, there are many examples in the 
literature of recent years of nanoemulsionloaded 
drugs with different therapeutic goals in brain 
diseases. The pathologies are all important and 
serious; many of these diseases, if not treated 
effectively, can reduce the quality of life or even lead 
to death. The nose-to-brain delivery is often an 
alternative to oral therapies for the CNS that can 
present problems, usually related to the 
characteristics of the drug. There are many reasons a 
CNS drug can be a good candidate for intranasal 
nanoemulsion, as an alternative to the oral 
administration (Table 1). However, as demonstrated 
by the reported literature, intranasal administrations 
of NEs often lead to better results, also with respect 
to intravenous administrations. These good results 
can be explained by mechanisms of 
transcytosis/endocytosis of the nanodroplets by the 
brain endothelial cells. Moreover, the surfactant(s) 
present in the nanoemulsions could have a fluidizing 
effect on endothelial cell membranes, determining an 
enhanced drug permeability and favoring by this 
mechanism the olfactory and trigeminal pathways. 
Nanoemulsions for nasal administration represent a 
promising strategy for nose-to-brain drug delivery 
and to achieve CNS targeting for the treatment of 
neurodiseases. However, clinical studies of these 
formulations are still needed to demonstrate their 
appropriateness in clinical practice. Many efforts 
must be made to further improve the performances of 
nanoemulsions. Future perspectives could consider 
the use of additional excipients. For instance, it is 
known that cyclodextrins can be used for the 
preparation of formulations able to cross the BBB, 
administered through nasal or oral/parenteral routes 
[16,23,56,57] . New penetration enhancers and 
modulators of cytochrome P450 Could be proposed 
to improve the selectivity and entity of penetration 
through the BBB . 
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